Improved performance parameters following oral live non-pathogenic *Escherichia coli* vaccination in piglets against post-weaning diarrhea

Vangroenweghe Frédéric¹

¹ Elanco Animal Health, BU Food Animals, ANTWERPEN, Belgium

Introduction & objective: Post-weaning *Escherichia coli* diarrhea (PWD), also called post-weaning enteric colibacillosis, in pigs remains a major cause of economic losses for the pig industry, due to either piglet death, or poor weight gain in surviving piglets [1,2]. PWD typically causes mild to severe watery diarrhea between 5 and 10 days after weaning and is primarily caused by enterotoxigenic *Escherichia coli* (ETEC). The most common adhesins found on ETEC from PWD in pigs are associated with fimbriae F4 (previously called K88) and F18, while the predominant enterotoxins are heat-labile toxin (LT), heat-stable toxin a (STa), and heat-stable toxin b (STb [3,4,5,6]. Therapy to control PWD typically consists of antibiotic treatment, addition of therapeutic doses of zinc oxide (ZnO; >2000 ppm, 14 days) and changes in feed composition of the post-weaning diets. The objective was to compare vaccination with Coliprotec® F4 (PrevTec Microbia), to two standard therapeutic approaches, namely ZnO (2500 ppm) and diet adaptations in combination with individual antibiotic treatment. The active vaccine strain in Coliprotec® F4 is one of the components of the bivalent Coliprotec® F4F18 (PrevTec Microbia) vaccine.

Material and methods: In a commercial 600-sow farm (DanBred sows x Piétrain) with PWD caused by F4-ETEC, piglets were vaccinated at 18 days of age with Coliprotec® F4. At weaning, piglets were randomly distributed into 5 groups with different treatments (Table 1). During the 7-week post-weaning period several technical production parameters (weight, average daily weight gain, feed intake, feed conversion rate, antibiotic treatment, mortality) were recorded. Statistical differences between groups were calculated using JMP® program.

Results: A summary of the obtained results is given in Table 1.

Table 1. Summary of trial outline and obtained performance results. Statistically different numbers are given with different superscripts.

Group	Α	В	С	D	E
Vaccination	+++	+++	+++		
Adapted safe diet				+++	
ZnO (2500 ppm, 14 days)					+++
Feeding strategy (number of feed phases)	1	2	3	3	3
Weight at weaning (kg)	5.29 a	5.34 ^a	5.31 ^a	5.33 a	5.44 a
Weight at 21 dpw* (kg)	7.45 a	7.69 a	7.42 a	7.01 ^b	8.74 °
Weight at 50 dpw (kg)	18.01 a	18.41 a	18.16 a	17.51 ^b	16.94 °
ADWG° (0-21 dpw) (g/d)	106 a	110 a	97 a	71 ^b	157°
ADWG (22-50 dpw) (g/d)	358 ª	365 a	372 a	358 a	276 b
ADWG (0-50 dpw) (g/d)	248 a	258 a	254 a	230 a	226 a
Feed consumption (0-21dpw; kg)	4.23 a	4.05 a	3.80 a	3.29 ^b	5.37°
Feed consumption (0-50dpw; kg)	21.43 a	20.58 a	20.38 a	20.36 a	21.62 a
FCR [®] (kg feed/ kg growth)	1.69 a	1,58 a	1,59°	1,67 a	1,88 ^b
Mortality (%)	4.7 a	3.9 a	3.1 a	12.5 b	7.0 b
Treatment incidence [†]	59.37 a	57.03 a	82.03 b	246.09 °	8.59 ^d
Average fecal score (0-4)	1.95 a	1.89 a	1.96 a	2.39 b	0.72 c
Financial net result (€/pig) compared to safe formulation	€ 5.28 a	€ 5.31 a	€ 5.23 a	€ 0.00 b	€ 0.95 °
nw – days nost-waaning: ° ADWG – ayaraga daily waight gain: ® FCR – fead conversion	n rate: † treatment inc	idence - numbe	r of treated nial	ate nor 100 nigle	te in trial

Conclusions & discussion: This comparative study clearly shows that vaccination against PWD with Coliprotec® F4 has several advantages on technical performance parameters. The type of diet (1-, 2- or 3- phase diet) did not have a significant effect on performance parameters. Overall, vaccination with Coliprotec® F4 combined a reduction of weight loss with reasonable antibiotic use. The use of safe diet formulation is not a sustainable solution, whereas supplementation of ZnO did not result in the most optimal results throughout the entire study period. In conclusion, control of PWD through oral vaccination is a good option in order to protect piglets from the negative clinical effects of F4-ETEC infection in the post-weaning period with a clear economical gain due to improved weight gain and reduced antibiotic use.

References: [1] van Beers-Schreurs et al., 1992. Veterinary Quarterly 14, 29-34. [2] Fairbrother et al., 2005. Animal Health Research Reviews 6, 17-39. [3] Kwon et al., 2002. The Veterinary Record 150, 35-37. [4] Frydendahl, 2002. Veterinary Microbiology 85, 169-182. [5] Chen et al., 2004. Veterinary Microbiology 103, 13-20. [6] Vu Khac et al., 2006. BMC Veterinary Research 2, 10.